Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Hrom

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Anti-Cancer Drugs|February 3, 2011
Oxaliplatin as a radiosensitizing agent in rectal cancerSergio Huerta, John Hrom
Journal of the Mississippi State Medical Association|March 19, 2009
A rare case of signet ring cell gastric adenocarcinomaAndrew Dickey, John Hrom
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|February 8, 2007
Staphylococcal scalded skin syndrome: a rare complication of a common pathogenMohit Ahuja, John Hrom, Amy Woods, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2010
Tissue microarray constructs to predict a response to chemoradiation in rectal cancerSergio Huerta, John Hrom, Xiaohuan Gao, et al.
Experimental Hematology|April 13, 2022
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimenDavid Daniely, Eli Forouzan, Tanya M Spektor, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2026
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, et al.
Nature Biotechnology|December 18, 2018
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identificationBrendan Bulik-Sullivan, Jennifer Busby, Christine D Palmer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Anti-Cancer Drugs|February 3, 2011
Oxaliplatin as a radiosensitizing agent in rectal cancerSergio Huerta, John Hrom
Journal of the Mississippi State Medical Association|March 19, 2009
A rare case of signet ring cell gastric adenocarcinomaAndrew Dickey, John Hrom
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|February 8, 2007
Staphylococcal scalded skin syndrome: a rare complication of a common pathogenMohit Ahuja, John Hrom, Amy Woods, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2010
Tissue microarray constructs to predict a response to chemoradiation in rectal cancerSergio Huerta, John Hrom, Xiaohuan Gao, et al.
Experimental Hematology|April 13, 2022
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimenDavid Daniely, Eli Forouzan, Tanya M Spektor, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2026
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, et al.
Nature Biotechnology|December 18, 2018
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identificationBrendan Bulik-Sullivan, Jennifer Busby, Christine D Palmer, et al.
Pageof 1